Radiolabelled probes for improved health


This research area focuses on the development of radioactive probes and imaging techniques which optimise the assessment of a functional status of a disease, and to tailor radio-ligands that enable the best therapeutic plan for patients.

 

The use of radiolabelled probes to improve health currently has two components:

 

  • Follow up of disease progression and therapy benefits
  • Help to adjust therapeutic strategy for each patient (personalised medicine)

 

This theme has three main research directions:

 

  1. To develop novel radiochemistry methodology and radiolabelling techniques to improve radiolabelling efficiencies, and to decrease radiolabelling time via macro and microfluidic and microwave technologies

  2. To develop novel radioligands (small molecules, peptides, proteins, cells or particles) for imaging (PET, SPECT) and targeted radioisotope therapy

  3. To optimise imaging and quantification techniques for new radio-isotopes and various organs of interest

 

Our current projects

 

Radiochemistry team

 

  • Development of radioautomation procedures for novel and existing 18F-synthons using automation modules

  • Development of ligands and analysis techniques for high valent, oxophillic radiometals

  • Development of [18F]synthons for protein and peptide conjugation

 

Investigations with imaging team

 

  • Quantification of whole-body mice with PET and SPECT

  • Quantification and cross-calibration of pre-clinical PET imaging with long half-life radioisotopes

 

Our collaborative work

 

  • Imaging altered drug clearance in cancer models using 99mTc-Sestamibi Learn more.
  • Biological evaluation of iodobenzamides for therapeutic malignant melanoma applications
  • Synthesis of Organic Cation Transporter 3 (OCT3) selective ligands for investigation of therapeutic potential in the treatment of psychiatric disorders
  • Development of novel macrocycles and chelation technologies for simple and rapid radiolabelling of small molecules, peptides, proteins and cells with radiometals (89Zr, 90Nb, 64Cu, 177Lu, and 68Ga) for imaging and therapy